

## DAFTAR PUSTAKA

- Abbas, A. K., Lichtman, A. H., & Pillai, S. (Eds.). (2017a). Differentiation and Functions of CD8+ Effector T Cells. In *Cellular and Molecular Immunology* (9th ed., pp. 243–250). Philadelphia: Elsevier.
- Abbas, A. K., Lichtman, A. H., & Pillai, S. (Eds.). (2017b). Immunity to Tumors. In *Cellular and Molecular Immunology* (9th ed., pp. 397–416). Philadelphia: Elsevier.
- Abbas, A. K., Lichtman, A. H., Pillai, S., Lichtman, A. H., & Pillai, S. (2016). *Basic Immunology: Functions and Disorders*. <https://doi.org/978-1-4557-0707-2>
- Abbas, A. K., Lichtman, A., & Pillai, S. (2017c). *Cellular and Molecular Immunology* (9th ed.). Philadelphia: Elsevier Inc.
- Abdelaal, W., Abbas, N., El-Sharkawy, S., Helmy, N. H., Badawi, M., Abouelfadl, D., ... Oda, O. (2019). Immunohistochemical expression of CD4+ and CD8+ tumor-infiltrating lymphocytes in colorectal carcinoma. *Journal of The Arab Society for Medical Research*, 14(2), 153. [https://doi.org/10.4103/jasmr.jasmr\\_22\\_19](https://doi.org/10.4103/jasmr.jasmr_22_19)
- AJCC. (2006). Colon and Rectum (Sarcomas, lymphomas, and carcinoid tumors of the large intestine or appendix are not included.). *American Joint Committee on Cancer*, 107–118. <https://doi.org/10.1186/1477-7800-3-34>
- Arnold, M., Sierra, M. S., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2017). Global patterns and trends in colorectal cancer incidence and mortality. *Gut*, 66(4), 683–691. <https://doi.org/10.1136/gutjnl-2015-310912>
- Chen. (2022). HHS Public Access. *Differential Pre-Malignant Programs and Microenvironment Chart Distinct Paths to Malignancy in Human Colorectal Polyps A*, 184(26), 6262–6280. <https://doi.org/10.1016/j.cell.2021.11.031>
- Chen, J., Gu, P., & Wu, H. (2020). Uncovering PD-L1 and CD8+TILS Expression and Clinical Implication in Cervical Squamous Cell Carcinoma. *BioMed Research International*, 2020. <https://doi.org/10.1155/2020/8164365>
- Deschoolmeester, V., Baay, M., Lardon, F., Pauwel, P., & Peeters, M. (2011). Immune cells in colorectal cancer: Prognostic relevance and role of MSI. *Cancer Microenvironment*, 4(3), 377–392. <https://doi.org/10.1007/s12307-011-0068-5>
- Devaud, C., Darcy, P. K., & Kershaw, M. H. (2014). Foxp3 expression in T regulatory cells and other cell lineages. *Cancer Immunology, Immunotherapy*, 63(9), 869–876. <https://doi.org/10.1007/s00262-014-1581-4>
- Dintinjana, R. D., Redzović, A., & Dintinjana, M. (2014). Molecular Pathways of Colorectal Carcinogenesis are Promising Mystery ?, 1–5. <https://doi.org/10.4172/2157-2518.S10-003>
- Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002a). Cancer immunoediting : from immuno- surveillance to tumor escape.

- Nature Immunology*, 3(11), 991–998. <https://doi.org/10.1038/ni1102-991>
- Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002b). Cancer Immunoediting : from Immunosurveillance to Tumor Escape. *Nature Publishing Group*, 3(11), 991–998.
- Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004). The Immunobiology of Cancer Immunosurveillance and Immunoediting. *Immunity*, 21, 137–148.
- Facciabene, A., Motz, G. T., & Coukos, G. (2012). T-Regulatory cells: Key players in tumor immune escape and angiogenesis. *Cancer Research*, 72(9), 2162–2171. <https://doi.org/10.1158/0008-5472.CAN-11-3687>
- Fleming, M., Ravula, S., Tatishchev, S. F., & Wang, H. L. (2012). Colorectal carcinoma: Pathologic aspects. *Journal of Gastrointestinal Oncology*. <https://doi.org/10.3978/j.issn.2078-6891.2012.030>
- Fletcher, R., Wang, Y.-J., Schoen, R. E., Finn, O. J., Yu, J., & Zhang, L. (2018). Colorectal cancer prevention: Immune modulation taking the stage. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*, 1869(2), 138–148. <https://doi.org/https://doi.org/10.1016/j.bbcan.2017.12.002>
- Grimmig, T., Kim, M., Germer, C. T., Gasser, M., & Waaga-Gasser, A. M. (2013). The role of FOXP3 in disease progression in colorectal cancer patients. *OncolImmunology*, 2(6). <https://doi.org/10.4161/onci.24521>
- Hu, W., Sun, R., Chen, L., Zheng, X., & Jiang, J. (2019). Prognostic significance of resident CD103+CD8+T cells in human colorectal cancer tissues. *Acta Histochemica*, 121(5), 657–663. <https://doi.org/10.1016/j.acthis.2019.05.009>
- Indiralia, A., Rahniayu, A., & Mustokoweni, S. (2018). Perbedaan Ekspresi Foxp3+ dan Cd8+ Tumor Infiltrating Lymphocytes Karsinoma Payudara pada Berbagai Stadium T. *Indonesian Journal of Cancer*, 12(1), 7. <https://doi.org/10.33371/ijoc.v12i1.549>
- Jakubowska, K., Kisielewski, W., Kańczuga-Koda, L., Koda, M., & Famulski, W. (2017). Stromal and intraepithelial tumor-infiltrating lymphocytes in colorectal carcinoma. *Oncology Letters*, 14(6), 6421–6432. <https://doi.org/10.3892/ol.2017.7013>
- Jia, H., Qi, H., Gong, Z., Yang, S., Ren, J., Liu, Y., ... Chen, G. G. (2019). The expression of FOXP3 and its role in human cancers. *Biochimica et Biophysica Acta - Reviews on Cancer*, 1871(1), 170–178. <https://doi.org/10.1016/j.bbcan.2018.12.004>
- Karanikas, V., Speletas, M., Zamanakou, M., Kalala, F., Loules, G., Kerenidi, T., ... Germentis, A. E. (2008). Foxp3 expression in human cancer cells. *Journal of Translational Medicine*, 8, 1–8. <https://doi.org/10.1186/1479-5876-6-19>
- Kim, M., Grimmig, T., Grimm, M., Lazariotou, M., Meier, E., Rosenwald, A., ... Gasser, M. (2013). Expression of Foxp3 in Colorectal Cancer but Not in Treg Cells Correlates with Disease Progression in Patients with Colorectal Cancer. *PLoS ONE*, 8(1). <https://doi.org/10.1371/journal.pone.0053630>

- Kumar, V., Abbas, A. K., & Aster, J. C. (2015). *Pathologic Basic of Disease. 9Ed.* Philadelphia: Elsevier.
- Kuwahara, T., Hazama, S., Suzuki, N., Yoshida, S., Tomochika, S., Nakagami, Y., ... Nagano, H. (2019). Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer. *British Journal of Cancer*, *121*(8), 659–665. <https://doi.org/10.1038/s41416-019-0559-6>
- Ladoire, S., Martin, F., & Ghiringhelli, F. (2011). Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: The paradox of colorectal cancer. *Cancer Immunology, Immunotherapy*, *60*(7), 909–918. <https://doi.org/10.1007/s00262-011-1046-y>
- Li, Z., Li, D., Tsun, A., & Li, B. (2015, September 8). FOXP3+ regulatory T cells and their functional regulation. *Cellular and Molecular Immunology*. Chinese Soc Immunology. <https://doi.org/10.1038/cmi.2015.10>
- Ling, A., Edin, S., Wikberg, M. L., Öberg, Å., & Palmqvist, R. (2014). The intratumoural subsite and relation of CD8+ and FOXP3 + T lymphocytes in colorectal cancer provide important prognostic clues. *British Journal of Cancer*, *110*(10), 2551–2559. <https://doi.org/10.1038/bjc.2014.161>
- Martin, F., Ladoire, S., Mignot, G., Apetoh, L., & Ghiringhelli, F. (2010). Human FOXP3 and cancer. *Oncogene*, *29*(29), 4121–4129. <https://doi.org/10.1038/onc.2010.174>
- Mescher, A. L. (2016). *Junqueira's Basic Histology* (Fourteenth). McGraw-Hill Education.
- Miskad, U. A., Hamzah, N., Cangara, M. H., Nelwan, B. J., Masadah, R., & Wahid, S. (2020). Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in colorectal adenocarcinoma. *Minerva Medica*, *111*(4), 337–343. <https://doi.org/10.23736/S0026-4806.20.06401-0>
- Nagtegaal, I. D., Arends, M. J., & M, S.-T. (2019). *WHO Classification of Tumours: Digestive System Tumours*. (The WHO Classification of Tumours Editorial Board, Ed.) (5th ed.). WHO Press.
- Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., Saigenji, K., Nagura, H., & Ohtani, H. (1998). CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. *Cancer Research*, *58*(16), 3491–3494.
- Norton, S. E., Ward-Hartstonge, K. A., Taylor, E. S., & Kemp, R. A. (2015). Immune cell interplay in colorectal cancer prognosis. *World Journal of Gastrointestinal Oncology*, *7*(10), 221. <https://doi.org/10.4251/wjgo.v7.i10.221>
- Ono, T., Azuma, K., Kawahara, A., Kakuma, T., Sato, F., Akiba, J., ... Umeno, H. (2020). Predictive value of CD8/FOXP3 ratio combined with PD-L1 expression for radiosensitivity in patients with squamous cell carcinoma of the larynx receiving definitive radiation therapy. *Head & Neck*, *42*(12), 3518–3530. <https://doi.org/10.1002/hed.26416>
- Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kühnel, F., & Woller, N. (2018, February 1). CD4 and CD8 T lymphocyte interplay in

- controlling tumor growth. *Cellular and Molecular Life Sciences*. Birkhauser Verlag AG. <https://doi.org/10.1007/s00018-017-2686-7>
- P.H, T., & Ellis, I. O. (Eds.). (2019). Introduction to Tumours of the Breast. In *WHO Classification of Tumours: Breast Tumours* (5th editio, pp. 6–7). Geneva: IARC publications. Retrieved from <https://publications.iarc.fr>
- Plitas, G., & Rudensky, A. Y. (2016). Regulatory T Cells: Differentiation and Function. *Cancer Immunol Res.*, 4(9), 721–725. <https://doi.org/10.1158/2326-6066>
- Ross, M. H., & Pawlina, W. (2011). *Histology : a text and atlas : with correlated cell and molecular biology* (Seventh). Philadelphia: Wolters Kluwer Health.
- Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008, May 30). Regulatory T Cells and Immune Tolerance. *Cell*. <https://doi.org/10.1016/j.cell.2008.05.009>
- Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., ... Loi, S. (2015, February 1). The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILS Working Group 2014. *Annals of Oncology*. Oxford University Press. <https://doi.org/10.1093/annonc/mdu450>
- Sideras, K., Galjart, B., Vasaturo, A., Pedroza-Gonzalez, A., Biermann, K., Mancham, S., ... Bruno, M. J. (2018). Prognostic value of intra-tumoral CD8<sup>+</sup>/FoxP3<sup>+</sup> lymphocyte ratio in patients with resected colorectal cancer liver metastasis. *Journal of Surgical Oncology*, 118(1), 68–76. <https://doi.org/10.1002/jso.25091>
- Stanley R. Hamilton, M. D., & Lauri A. Aaltonen, M.D., P. D. (2000). *World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Digestive System* (Vol. 18). <https://doi.org/10.1183/09031936.01.00275301>
- Stewart, S. L., Wike, J. M., Kato, I., Lewis, D. R., & Michaud, F. (2006). A population-based study of colorectal cancer histology in the United States, 1998-2001. *Cancer*, 107(SUPPL.), 1128–1141. <https://doi.org/10.1002/cncr.22010>
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/caac.21660>
- Suzuki, H., Chikazawa, N., Tasaka, T., Wada, J., Yamasaki, A., Kitaura, Y., ... Katano, M. (2010). Intratumoral CD8<sup>+</sup> T/FOXP3<sup>+</sup> cell ratio is a predictive marker for survival in patients with colorectal cancer. *Cancer Immunology, Immunotherapy*, 59(5), 653–661. <https://doi.org/10.1007/s00262-009-0781-9>
- Treuting, P. M., Arends, M. J., & Dintzis, S. M. (2018). *Comparative Anatomy and Histology*. (P. M. Treuting, S. M. Dintzis, & K. S. Montine, Eds.) (second). United Kingdom: Elsevier Inc.
- Wahid, S., & Miskad, U. A. (2016). *Imunologi: Lebih Mudah Dipahami*. Surabaya: Brilian Internasional.

- Whiteside, T. L. (2012). What are regulatory T cells (Treg) regulating in cancer and why? *Seminars in Cancer Biology*, 22(4), 327–334. <https://doi.org/10.1016/j.semcancer.2012.03.004>
- Zhu, Y., Li, M., Mu, D., Kong, L., Zhang, J., Zhao, F., ... Yu, J. (2016). CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. *Oncotarget*, 7(44), 71455–71465. <https://doi.org/10.18632/oncotarget.12213>

LAMPIRAN  
 Persetujuan Etik



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI  
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN  
 KOMITE ETIK PENELITIAN KESEHATAN  
 RSPTN UNIVERSITAS HASANUDDIN  
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR  
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu  
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.  
 Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431



**REKOMENDASI PERSETUJUAN ETIK**

Nomor : 468/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 22 Juli 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21070449	No Sponsor Protokol	
Peneliti Utama	<b>dr. Ummu Kalzum Malik</b>	Sponsor	
Judul Peneliti	EKSPRESI CD8+ SEL T SITOTOKSIK DAN EKSPRESI FOXP3+ SEL T REGULATOR PADA TUMOR-INFILTRATING LYMPHOCYTES (TILS) ADENOKARSINOMA KOLOREKTAL		
No Versi Protokol	<b>1</b>	Tanggal Versi	<b>14 Juli 2021</b>
No Versi PSP		Tanggal Versi	
Tempat Penelitian	Laboratorium PA Fakultas Kedokteran Universitas Hasanuddin Makassar		
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku <b>22 Juli 2021</b> sampai <b>22 Juli 2022</b>	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama <b>Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)</b>	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama <b>dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)</b>	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

**Descriptives**

Derajat Differensiasi				Statistic	Std. Error
Umur	Low Grade	Mean		55.66	1.482
		95% Confidence Interval for Mean	Lower Bound	52.69	
			Upper Bound	58.63	
		5% Trimmed Mean		56.09	
		Median		55.00	
		Variance		129.607	
		Std. Deviation		11.385	
		Minimum		22	
		Maximum		76	
		Range		54	
		Interquartile Range		16	
		Skewness		-.547	.311
		Kurtosis		.322	.613
		High Grade	High Grade	Mean	
95% Confidence Interval for Mean	Lower Bound			52.23	
	Upper Bound			64.50	
5% Trimmed Mean				58.94	
Median				62.00	
Variance				191.290	
Std. Deviation				13.831	
Minimum				27	
Maximum				79	
Range				52	
Interquartile Range				18	
Skewness				-.774	.491
Kurtosis				-.022	.953
CD8	Low Grade			Mean	
		95% Confidence Interval for Mean	Lower Bound	164.3466	
			Upper Bound	214.4805	

		5% Trimmed Mean		182.2392	
		Median		173.5000	
		Variance		9252.284	
		Std. Deviation		96.18880	
		Minimum		60.20	
		Maximum		458.40	
		Range		398.20	
		Interquartile Range		110.80	
		Skewness		1.078	.311
		Kurtosis		.970	.613
High	Grade	Mean		116.1864	20.73028
		95% Confidence Interval for	Lower	73.0754	
		Mean	Bound		
			Upper	159.2973	
			Bound		
		5% Trimmed Mean		105.8515	
		Median		75.0000	
		Variance		9454.377	
		Std. Deviation		97.23362	
		Minimum		15.10	
		Maximum		419.90	
		Range		404.80	
		Interquartile Range		148.50	
		Skewness		1.621	.491
		Kurtosis		3.148	.953
FOXP3	Low Grade	Mean		41.3723	3.80391
		95% Confidence Interval for	Lower	33.7579	
		Mean	Bound		
			Upper	48.9866	
			Bound		
		5% Trimmed Mean		38.6983	
		Median		36.7470	
		Variance		853.715	
		Std. Deviation		29.21841	
		Minimum		.00	
		Maximum		158.43	
		Range		158.43	
		Interquartile Range		31.93	
		Skewness		1.680	.311



		Kurtosis		3.932	.613
High		Mean		67.4425	11.34262
Grade		95% Confidence Interval for	Lower	43.8542	
		Mean	Bound		
			Upper	91.0308	
			Bound		
		5% Trimmed Mean		62.5624	
		Median		58.7349	
		Variance		2830.409	
		Std. Deviation		53.20158	
		Minimum		14.46	
		Maximum		215.06	
		Range		200.60	
		Interquartile Range		78.77	
		Skewness		1.079	.491
		Kurtosis		1.076	.953
CD8/FOXP3	Low Grade	Mean		6.3544	.94276
		95% Confidence Interval for	Lower	4.4673	
		Mean	Bound		
			Upper	8.2415	
			Bound		
		5% Trimmed Mean		5.4662	
		Median		4.8600	
		Variance		52.439	
		Std. Deviation		7.24148	
		Minimum		.00	
		Maximum		55.14	
		Range		55.14	
		Interquartile Range		5.31	
		Skewness		5.451	.311
		Kurtosis		36.342	.613
High		Mean		3.6909	.99665
Grade		95% Confidence Interval for	Lower	1.6183	
		Mean	Bound		
			Upper	5.7636	
			Bound		
		5% Trimmed Mean		3.2352	
		Median		1.4350	

Variance	21.853	
Std. Deviation	4.67471	
Minimum	.21	
Maximum	15.40	
Range	15.19	
Interquartile Range	5.18	
Skewness	1.600	.491
Kurtosis	1.580	.953

## Mann-Whitney Test

		Ranks		
Derajat Differensiasi		N	Mean Rank	Sum of Ranks
CD8	Low Grade	59	46.47	2741.50
	High Grade	22	26.34	579.50
	Total	81		
FOXP3	Low Grade	59	38.41	2266.00
	High Grade	22	47.95	1055.00
	Total	81		
CD8/FOXP3	Low Grade	59	45.96	2711.50
	High Grade	22	27.70	609.50
	Total	81		

Test Statistics <sup>a</sup>			
	CD8	FOXP3	CD8/FOXP3
Mann-Whitney U	326.500	496.000	356.500
Wilcoxon W	579.500	2266.000	609.500
Z	-3.424	-1.625	-3.106
Asymp. Sig. (2-tailed)	.001	.104	.002

a. Grouping Variable: Derajat Differensiasi

## Derajat Differensiasi \* Ekspresi CD8/FOXP3

			Crosstab		
			Ekspresi CD8/FOXP3		
			Low Density	High Density	Total
Derajat Differensiasi	Low Grade	Count	25	34	59
		% of Total	30.9%	42.0%	72.8%
	High Grade	Count	16	6	22
		% of Total	19.8%	7.4%	27.2%
Total	Count	41	40	81	
	% of Total	50.6%	49.4%	100.0%	

### Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	5.907 <sup>a</sup>	1	.015		
Continuity Correction <sup>b</sup>	4.755	1	.029		
Likelihood Ratio	6.082	1	.014		
Fisher's Exact Test				.024	.014
Linear-by-Linear Association	5.834	1	.016		
N of Valid Cases	81				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 10,86.

b. Computed only for a 2x2 table

□

### Derajat Differensiasi \* Ekspresi CD8

#### Crosstab

			Ekspresi CD8		Total
			Low Density	High Density	
Derajat Differensiasi	Low Grade	Count	25	34	59
		% of Total	30.9%	42.0%	72.8%
	High Grade	Count	15	7	22
		% of Total	18.5%	8.6%	27.2%
Total	Count	40	41	81	
	% of Total	49.4%	50.6%	100.0%	

### Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	4.270 <sup>a</sup>	1	.039		
Continuity Correction <sup>b</sup>	3.300	1	.069		
Likelihood Ratio	4.343	1	.037		
Fisher's Exact Test				.048	.034
Linear-by-Linear Association	4.218	1	.040		
N of Valid Cases	81				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 10,86.

b. Computed only for a 2x2 table

## Derajat Differensiasi \* Ekspresi FOXP3

### Crosstab

			Ekspresi FOXP3		Total
			Low Density	High Density	
Derajat Differensiasi	Low Grade	Count	30	29	59
		% of Total	37.0%	35.8%	72.8%
	High Grade	Count	10	12	22
		% of Total	12.3%	14.8%	27.2%
Total	Count		40	41	81
	% of Total		49.4%	50.6%	100.0%

### Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.186 <sup>a</sup>	1	.666		
Continuity Correction <sup>b</sup>	.033	1	.856		
Likelihood Ratio	.187	1	.666		
Fisher's Exact Test				.804	.428
Linear-by-Linear Association	.184	1	.668		
N of Valid Cases	81				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 10,86.

b. Computed only for a 2x2 table